NEW HOPE ON THE HORIZON FOR PATIENTS WITH SCLC .
Ariel Lopez-Chavez, MD
Trials Are Currently Ongoing, Investigating Novel Agents For The Potential Treatment Of SCLC . Investigators On These Studies Aim To Address The High Unmet Needs In SCLC .
Lopez-Chavez Discusses Promising NEW Avenues For SCLC Treatment, Including With An Investigational GM1 ANTIBODY By Bristol Myers Squibb Which Showed Encouraging Results In COMBINATION With NIVOLUMAB ( OPDIVO ) in the SECOND-LINE Setting .
The Agent Achieved An 18-Month Median OVERALL SURVIVAL And Trials Are Ongoing For Its Use In Both Frontline And Combination With STANDAR CHEMOTHERAPY PLUS
NIVOLUMAB .
Additionally, Lopez-Chavez Highlights The Potential of Radionuclide Therapy For Frontline SCLC And The Exploration Of Cellular Therapies, Which Are Similar To Those Being Investigated in the NON-SMALL CELL LUNG CÁNCER Space .
TRANSCRIPTIÓN : 0:09 |
There Are Ones That Are Currently Going Towards Registration … And We Have Another GM1 ANTIBODY By [ Bristol Myers Squibb ] .
That One Looked Interesting In Their Initial Results In The Refractory Setting .
They Are Bringing it Into The Frontline Setting As Well .
They Are Also Studying It In Combination With CARBOPLATIN, ETOPÓSIDE, And NIVOLUMAB .The Results Were Not As Impressive As With The Latter, But It Is Something To Follow-Up On .
1:09 | We Also Have Radionuclide Therapy Also Coming Into The Frontline Setting … On More Space That I Am Interested In Is The Use Of Cellular Therapies . A Lot Of Companies Are Going In The Space Of Cellular Therapies, In Solid Tumors, In Particular In NON-SMALL CELL LUNG CÁNCER, And There Are Some Studies Now Going Into SMALL CELL LUNG CÁNCER . That Will Be Interesting To See What Therapies Are Capable Of .